DE3587022D1 - Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. - Google Patents

Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.

Info

Publication number
DE3587022D1
DE3587022D1 DE8585301037T DE3587022T DE3587022D1 DE 3587022 D1 DE3587022 D1 DE 3587022D1 DE 8585301037 T DE8585301037 T DE 8585301037T DE 3587022 T DE3587022 T DE 3587022T DE 3587022 D1 DE3587022 D1 DE 3587022D1
Authority
DE
Germany
Prior art keywords
alpha
precursor
tgf
growth factor
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585301037T
Other languages
English (en)
Other versions
DE3587022T2 (de
Inventor
Rik Michel Andre Derynck
David Vannorman Goeddel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE3587022D1 publication Critical patent/DE3587022D1/de
Application granted granted Critical
Publication of DE3587022T2 publication Critical patent/DE3587022T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
DE8585301037T 1984-02-17 1985-02-15 Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. Expired - Lifetime DE3587022T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58174384A 1984-02-17 1984-02-17
US06/695,494 US4742003A (en) 1984-02-17 1985-05-14 Human transforming growth factor

Publications (2)

Publication Number Publication Date
DE3587022D1 true DE3587022D1 (de) 1993-03-11
DE3587022T2 DE3587022T2 (de) 1993-06-17

Family

ID=27078409

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585301037T Expired - Lifetime DE3587022T2 (de) 1984-02-17 1985-02-15 Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.

Country Status (5)

Country Link
US (1) US4742003A (de)
EP (1) EP0154434B1 (de)
AT (1) ATE85080T1 (de)
CA (1) CA1341227C (de)
DE (1) DE3587022T2 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
US5656587A (en) * 1982-09-24 1997-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Promotion of cell proliferation by use of transforming growth factor beta (TGF-β)
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
AU5249786A (en) * 1985-01-29 1986-08-07 Oncogen Wound healing compositions
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
WO1986006076A1 (en) * 1985-04-18 1986-10-23 Biotechnology Australia Pty. Ltd. Recombinant inhibin
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US5130300A (en) * 1986-03-07 1992-07-14 Monsanto Company Method for enhancing growth of mammary parenchyma
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US6994988B1 (en) * 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5226912A (en) 1987-08-26 1993-07-13 United States Surgical Corporation Combined surgical needle-braided suture device
US5306289A (en) * 1987-08-26 1994-04-26 United States Surgical Corporation Braided suture of improved characteristics
US5366081A (en) 1987-08-26 1994-11-22 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5222978A (en) 1987-08-26 1993-06-29 United States Surgical Corporation Packaged synthetic absorbable surgical elements
US5472702A (en) * 1987-08-26 1995-12-05 United States Surgical Corporation Sterilization of growth factors
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
EP0339905A3 (de) * 1988-04-25 1991-05-08 Ethicon, Inc. Wachstumfaktoren und Retinoiden enthaltende Wundheilungzusammensetzungen
US5256644A (en) * 1988-05-20 1993-10-26 Institute Of Molecular Biology, Inc. Wound healing using IGF-II and TGF
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5034375A (en) * 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5304541A (en) * 1988-12-15 1994-04-19 Bristol-Myers Squibb Company Methods using novel chimeric transforming growth factor-β1/β2
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
US5182261A (en) * 1989-07-13 1993-01-26 The Rockefeller University Modified transforming growth factor alpha oligopeptides and pharmaceutical compositions thereof
US5246104A (en) * 1989-08-01 1993-09-21 United States Surgical Corporation Molded suture retainer
US5359831A (en) 1989-08-01 1994-11-01 United States Surgical Corporation Molded suture retainer
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US5849694A (en) * 1990-07-16 1998-12-15 Synenki; Richard M. Stable and bioactive modified porcine somatotropin and pharmaceutical compositions thereof
US5360790A (en) * 1990-12-11 1994-11-01 The Regents Of The University Of Michigan Method and formulations for the therapy of acute renal failure
US20040175795A1 (en) * 1991-09-20 2004-09-09 Amgen Inc. Glial derived neurotrophic factor
HU220795B1 (hu) * 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
WO1993010215A1 (en) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
CA2149441C (en) * 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
CA2215350C (en) * 1995-05-19 2011-07-26 Human Genome Sciences, Inc. Transforming growth factor alpha hii
EP1881069A1 (de) * 1995-05-19 2008-01-23 Human Genome Sciences, Inc. Transformierender Wachstumsfaktor alpha HII
US6410506B1 (en) 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US5858669A (en) * 1996-09-13 1999-01-12 The Trustees Of Columbia University In The City Of New York Beclin, a novel bcl-2 interacting gene near BRCA1 on chromosome 17q21 and methods of use
WO2000034310A1 (en) * 1998-12-10 2000-06-15 Vanderbilt University Purified and isolated serine-threonine kinase receptors associated protein
US6770458B1 (en) 1998-12-10 2004-08-03 Vanderbilt University Purified and isolated serine-threonine kinase receptors associated protein and use of same in the modulation of the biological activity of TGF-β
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
DE60035192T2 (de) 1999-04-26 2008-02-14 Applied Protein Sciences, LLC, Mountain View Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
CA2377371A1 (en) * 1999-06-22 2000-12-28 David N. Herndon Enhanced wound coverage to enhance wound healing
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US6677307B2 (en) 1999-08-19 2004-01-13 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
US20020077291A1 (en) * 2000-09-22 2002-06-20 Alan Upshall Method of treatment of tumors using transforming growth factor-alpha
JP3712393B2 (ja) 2000-10-20 2005-11-02 エーザイ株式会社 含窒素芳香環誘導体
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CA2536146A1 (en) * 2003-08-19 2005-02-24 Agos Biotech Ltd. Splice variants of erbb ligands, compositions and uses thereof
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP1765981A4 (de) * 2004-06-11 2007-09-12 Victorian Tissue Engineering C Gewebematerial und aus muskel gewonnene matrix
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP1925941B1 (de) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
WO2007015578A1 (ja) * 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
AU2006285673B2 (en) * 2005-09-01 2010-12-02 Eisai R&D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegratability
EP1949902B1 (de) 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. Verwendung einer kombination einer anti-angiogenen substanz und c-kit-kinase-hemmer
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
WO2008026748A1 (fr) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
EP2119707B1 (de) * 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
EP2209808B1 (de) 2007-10-19 2014-01-15 Genentech, Inc. Cysteinmodifizierte anti-tenb2-antikörper und antikörper-arzneimittel-konjugate
EP2218712B1 (de) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Kombination einer antiangiogenen substanz und eines platinkomplexes mit antitumorwirkung
CN102036962B (zh) * 2008-01-29 2013-08-07 卫材R&D管理有限公司 血管生成抑制剂和紫杉烷的组合使用
AU2011232435B2 (en) 2010-03-23 2016-01-28 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
MX2017001980A (es) 2014-08-28 2017-05-04 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y metodo para su produccion.
BR112017017428A2 (pt) 2015-02-25 2018-04-03 Eisai R&D Management Co., Ltd. ?método para supressão do amargor de derivado de quinolina?
KR20170122809A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4358586A (en) * 1980-12-23 1982-11-09 Harvey Rubin Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IE57724B1 (en) * 1983-05-09 1993-03-24 Todaro George Joseph Biologically active polypeptides
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985002198A1 (en) * 1983-11-01 1985-05-23 Amgen Microbial expression of type i transforming growth factor, polypeptide analogs thereof and hybrid egf/tgf polypeptides

Also Published As

Publication number Publication date
EP0154434B1 (de) 1993-01-27
EP0154434A1 (de) 1985-09-11
CA1341227C (en) 2001-05-15
ATE85080T1 (de) 1993-02-15
DE3587022T2 (de) 1993-06-17
US4742003A (en) 1988-05-03

Similar Documents

Publication Publication Date Title
DE3587022D1 (de) Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
MacDonald et al. Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate.
DE69320389T2 (de) Verfahren zur Herstellung des Inhibitors für die Komplexbildung des Gewebefaktors
ES540881A0 (es) Procedimiento para producir vectores hibridos de levadura
ES2085245T1 (es) Procedimiento para aislar acido nucleico.
ATE91629T1 (de) Adhesin-antigene, antikoerper und dns-fragmente die das antigen kodieren, verfahren und mittel zur diagnose und immunisierung, usw.
CA2050058A1 (en) Recombinant mite allergen
DE3806565A1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
HUT44433A (en) Process for preparing compositions comprising unsaturated fatty acids necessary for the synthesis of prostaglandines and hydroxy-fatty acids in biological systems
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
Fullmer et al. Human gingival collagenase: purification, molecular weight, and inhibitor studies
DE59008949D1 (de) hPTH-FRAGMENT-(1-37), SEINE HERSTELLUNG, DIESES ENTHALTENDE ARZNEIMITTEL UND SEINE VERWENDUNG.
DE3877669D1 (de) Verfahren zur kristallmorphologischen blut- und harnanalyse, zur fruehdiagnose und zur herstellung von arzneimitteln.
AU4492393A (en) Bone-related carboxypeptidase-like protein and process for its production
Jörgensen et al. Serogenetic investigations on malignant melanomas with reference to the incidence of AB0 system, Rh system, Gm, Inv, Hp and Gc systems
ATE512216T1 (de) Nukleinsäure und dieser entsprechendes, 184p1e2 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
EP0292663A1 (de) Verfahren zur Herstellung von Vitronectin
Willstätter Problems and methods in enzyme research
ATE127842T1 (de) Megakaryocytopoietin, seine herstellung und benutzung.
CA2047718A1 (en) Purified ciliary neurotrophic factor
EP0390829B1 (de) Verfahren zur erzeugung syngener zellen und deren verwendung
RU2288729C2 (ru) Способ выделения коллагена из костной ткани сельскохозяйственных животных
Philipov et al. A clinical study on the therapeutic effect of bee products on trophic chronic varicoses ulcerations of the inferior limbs
SU583107A1 (ru) Способ термообработки цементной сырьевой смеси
Lang et al. Yugoslavia: equity and imported ethical dilemmas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition